February 27, 2017 9:31 PM ET


Company Overview of Vaxil Bio Ltd.

Company Overview

Vaxil Bio Ltd., a clinical stage biotechnology company, engages in the development of novel, immunotherapeutic products, peptides, and antibodies for the treatment of cancer and infectious diseases in Israel. The company’s lead product is ImMucin, a multi-epitope cancer vaccine to the MUC1 tumor associated antigen that completed Phase II clinical trials; and is in Phase I/II clinical trials for the treatment of metastatic breast cancer patients in combination with hormonal therapy. It also develops MTbuVax, a multi-antigenic and multi-epitope subunit vaccine, which is in preclinical stage to treat intracellular pathogenic bacteria mycobacterium tuberculosis; and SPmAb, an antibody for the di...

4576 Yonge Street

6th Floor

Toronto, ON 


Founded in 2006

Key Executives for Vaxil Bio Ltd.

Vaxil Bio Ltd. does not have any Key Executives recorded.

Vaxil Bio Ltd. Key Developments

Vaxil Bio Ltd. Presents at 19th Annual BIO CEO & Investor Conference, Feb-14-2017 10:00 AM

Vaxil Bio Ltd. Presents at 19th Annual BIO CEO & Investor Conference, Feb-14-2017 10:00 AM. Venue: The Waldorf Astoria New York, 301 Park Avenue, New York, NY 10022, United States. Speakers: Limor Chen.

Vaxil Bio Ltd. Announces Executive Changes

Vaxil Bio Ltd. announced a collaboration with Hadassah Medical Center. In addition to the Vaxil-Hadassah Collaboration, Hadassah scientist Professor Michael Shapira will be joining the Vaxil Scientific Advisory Board. Furthermore, Vaxil is pleased to announced the appointment of Mr. Gadi Levin as interim CEO and as a Director of the Board. Mr. Levin has a strong financial background combined with a successful track record in the biotech field. Previously, Mr. Levin was the Chief Financial Officer of Labstyle Innovations Ltd. Dr. Benjamin Chen has resigned as CEO effective immediately. Dr. Chen will remain on the Vaxil Board of Directors where his focus will primarily pertain to scientific and strategic guidance.

Vaxil Bio Ltd. Announces Management Changes

Vaxil Bio Ltd. (formerly Emerge Resources Corp.) announced the closing of its reverse takeover acquisition of Vaxil Bio Ltd., following approval of the transaction and related matters by the shareholders of each of the company and Vaxil Israel. Following closing of the transaction, the company will principally conduct the biotech business of Vaxil Israel, and the board and management of the company will be as follows: Dr. Saeid Babaei - Director and Chairman, Dr. Lior Carmon - Director, Dr. Benjamin Chen - Director and CEO, Dr. Marian Gorecki - Director, Mr. Gadi Levin - CFO and Mr. Isaac Maresky - Executive Director.

Similar Private Companies By Industry

Company Name Region
2007262 Ontario, Inc. Americas
2056273 Ontario, Inc. Americas
AB BioPharma Inc. Americas
AbCelex Technologies Inc. Americas
AbCellera Biologics Inc. Americas

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Vaxil Bio Ltd., please visit www.vxlbio.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.